To be a global healthcare company based both in Korea and U.S. through a shortening period of new drug development is pH Pharma’s goal. Hitnews went through pH Pharma from the date of foundation to the current.(For more information, please refer to the link below) http://www.hitnews.co.kr/news/articleView.html?idxno=8045
Announcement of par value division
download download
pH Pharma, New Drug for Normal-Pressure Glaucoma “Result of Clinical Phase 2b”
Result of clinical phase 2b of PHP-201, new drug candidate for glaucoma treatment, announced in 2019 APAO in Bangkok(For more information, please refer to the link below)http://www.biospectator.com/view/news_view.php?varAtcId=7329
pH Pharma “Plan to finalize licensing-out of glaucoma treatment…Initiate to go IPO”
“We are fast bio ventures with Development and Research model” Jaesik Kim, CEO, says(For more information, please refer to the link below)http://www.thebell.co.kr/free/content/ArticleView.asp?key=201903040100002050000125&lcode=00&page=1&svccode=00
New stock issuance notice
On February 28, 2019, the same contents as attached will be announced (notified) by resolution of the board of directors. download download
pH Pharma getting attention for its ‘license out’ during Pre-IPO
PH Pharma, which develops a treatment for glaucoma and non-alcoholic steatohepatitis (NASH), is conducting a pre-IPO (attracting funds before listing) worth 15 billion won. It is a form of large-scale purchase of new stocks (including preferred stocks) by domestic securities companies and management companies. The final goal is to be...
New stock issuance notice
The same contents as attached will be announced (notified) by a resolution of the board of directors on February 12, 2019. download download
Announcement of issuance of new shares
The same contents as attached will be announced (notified) by the resolution of the board of directors on January 31, 2019. download download
Bio listing rush this year… Breaking all-time record
Over 20 bio ventures in progress of IPO… KRX supports bio listing (For more information, please refer to the link below)http://news.mt.co.kr/mtview.php?no=2019012814232589614&type=1
pH Pharma, bio venture, goes IPO onto KOSDAQ in the second half of this year
“Target to complete tech evaluation in first half… Expect licensing-out deal” Jaesik Kim, CEO, says(For more information, please refer to the link below)http://news.mt.co.kr/mtview.php?no=2019011514200854887&type=1